Therapeutic strategies in the treatment of diabetic nephropathy - A translational medicine approach

Current Medicinal Chemistry

Volumn 16, Issue 8, 2009, Pages 997-1016

  Shah, Imtiaz M ^a   Mackay, Simon P ^a   McKay, Gerard A ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Diabetic nephropathy; Growth factors; Hyperglycaemia; Inflammatory mediators; Oxidative stress; Renin angiotensin aldosterone system; Translational medicine; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FASUDIL; GLITAZONE DERIVATIVE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; PARICALCITOL; PENTOXIFYLLINE; PROTEIN KINASE C; PYRIDOXAMINE; RALOXIFENE; RAMIPRIL; RANIRESTAT; RECOMBINANT ERYTHROPOIETIN; RIMONABANT; RUBOXISTAURIN; SPIRONOLACTONE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D;

ALBUMINURIA; ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FUNCTION TEST; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PODOCYTE; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL MEDICINE; DIABETIC NEPHROPATHIES; DRUG DESIGN; HUMANS; HYPERGLYCEMIA; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION;

EID: 65649098711     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787581897     Document Type: Review

References (334)

1. Romao, I.; Roth, J. Genetic and environmental interactions in obesity and type 2 diabetes. J. Am. Diet. Assoc., 2008, 108, S24-S28.
2. Smyth, S.; Heron, A. Diabetes and obesity: The twin epidemics. Nat. Med., 2006, 12, 75-80.
3. Bloomgarden, Z. T. Diabetic nephropathy. Diabetes Care, 2008, 31, 823-827.
4. Whaley-Connell, A. T.; Sowers, J. R.; McFarlane, S. I.; Norris, K. C.; Chen, S. C.; Li, S.; Qiu, Y.; Wang, C.; Stevens, L. A.; Vassalotti, J. A.; Collins, A. J. Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am. J. Kidney Dis., 2008, 51, S21-S29.
5. Brosius, F. C., III; Hostetter, T. H.; Kelepouris, E.; Mitsnefes, M. M.; Moe, S. M.; Moore, M. A.; Pennathur, S.; Smith, G. L.; Wilson, P. W. F. Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease: A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration With the National Kidney Foundation. Circulation, 2006, 114, 1083-1087.
6. Koren-Morag, N.; Goldbourt, U.; Tanne, D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology, 2006, 67, 224-228.
7. Nag, S.; Bilous, R.; Kelly, W.; Jones, S.; Roper, N.; Connolly, V. All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study. Diabetes Med., 2007, 24, 10-17.
8. de Zeeuw, D.; Parving, H. H.; Henning, R. H. Microalbuminuria as an early marker for cardiovascular disease. J. Am. Soc. Nephrol., 2006, 17, 2100-2105.
9. Jude, E. B.; Anderson, S. G.; Cruickshank, J. K.; Srivatsa, A.; Tentolouris, N.; Chandrasekaran, R.; Gokal, R.; Boulton, A. J. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. QJM, 2002, 95, 371-377.
10. Satchell, S. C.; Tooke, J. E. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia, 2008, 51, 714-725.
11. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
12. Fioretto, P.; Solini, A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J. Am. Soc. Nephrol., 2005, 16, S18-S21.
13. Home, P.; Mant, J.; Diaz, J.; Turner, C. Management of type 2 diabetes: summary of updated NICE guidance. BMJ, 2008, 336, 1306-1308.
14. Palmer, B. F. Management of hypertension in patients with chronic kidney disease and diabetes mellitus. Am. J. Med., 2008, 121, S16-S22.
15. Qian, Y.; Feldman, E.; Pennathur, S.; Kretzler, M.; Brosius, F. C., III From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes, 2008, 57, 1439-1445.
16. Fioretto, P.; Mauer, M. Histopathology of diabetic nephropathy. Semin. Nephrol., 2007, 27, 195-207.
17. Ruggenenti, P.; Remuzzi, G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol. Dial. Transplant., 2000, 15, 1900-1902.
18. Moriya, T.; Tanaka, K.; Hosaka, T.; Hirasawa, Y.; Fujita, Y. Renal structure as an indicator for development of albuminuria in normoand microalbuminuric type 2 diabetic patients. Diabetes Res. Clin. Pract., 2008, 82, 298-304.
19. Marrero, M. B.; Fulton, D.; Stepp, D.; Stern, D. M. Angiotensin II-Induced Signaling Pathways in Diabetes. Curr. Diabetes Rev., 2005, 1, 197-202.
20. Navarro-Gonzalez, J. F.; Mora-Fernandez, C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol., 2008, 19, 433-442.
21. Zhu, Y.; Usui, H. K.; Sharma, K. Regulation of transforming growth factor beta in diabetic nephropathy: Implications for treatment. Semin. Nephrol., 2007, 27, 153-160.
22. Miyata, T.; Yamamoto, M.; Izuhara, Y. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy. Ann. N. Y. Acad. Sci., 2005, 1043, 740-749.
23. Happich, M.; Landgraf, R.; Piehlmeier, W.; Falkenstein, P.; Stamenitis, S. The economic burden of nephropathy in diabetic patients in Germany in 2002. Diabetes Res. Clin. Pract., 2008, 80, 34-39
24. Biswas, S. K.; Peixoto, E. B.; Souza, D. S.; de Faria, J. B. Hypertension increases pro-oxidant generation and decreases antioxidant defense in the kidney in early diabetes. Am. J. Nephrol., 2008, 28, 133-142.
25. Liao, T. D.; Yang, X. P.; Liu, Y. H.; Shesely, E. G.; Cavasin, M. A.; Kuziel, W. A.; Pagano, P. J.; Carretero, O. A. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension, 2008, 52, 256-263.
26. Croom, K. F.; Plosker, G. L. Irbesartan: A review of its use in hypertension and diabetic nephropathy. Drugs, 2008, 68, 1543-1569.
27. Brenner, B. M.; Cooper, M. E.; de Zeeuw, D.; Keane, W. F.; Mitch, W. E.; Parving, H. H.; Remuzzi, G.; Snapinn, S. M.; Zhang, Z.; Shahinfar, S.; the, R. S., I Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
28. Lacourciere, Y.; Belanger, A.; Godin, C.; Halle, J. P.; Ross, S.; Wright, N.; Marion, J. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int., 2000, 58, 762-769.
29. Lewis, E. J.; Hunsicker, L. G.; Clarke, W. R.; Berl, T.; Pohl, M. A.; Lewis, J. B.; Ritz, E.; Atkins, R. C.; Rohde, R.; Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
30. Parving, H. H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med., 2001, 345, 870-878.
31. Sarafidis, P. A.; Stafylas, P. C.; Kanaki, A. I.; Lasaridis, A. N. Effects of Renin-Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis. Am. J. Hypertens., 2008, 21, 922-929.
32. Cravedi, P.; Ruggenenti, P.; Remuzzi, G. Intensified inhibition of renin-angiotensin system: A way to improve renal protection? Curr. Hypertens. Rep., 2007, 9, 430-436.
33. MacKinnon, M.; Shurraw, S.; Akbari, A.; Knoll, G. A.; Jaffey, J.; Clark, H. D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am. J. Kidney Dis., 2006, 48, 8-20.
34. Song, J. H.; Cha, S. H.; Hong, S. B.; Kim, D. H. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J. Hypertens. Suppl., 2006, 24, S101-S106.
35. Knudsen, S. T.; Andersen, N. H.; Poulsen, S. H.; Eiskjaer, H.; Hansen, K. W.; Helleberg, K.; Poulsen, P. L.; Mogensen, C. E. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: A CALM II study post-hoc analysis. Am. J. Hypertens., 2008, 21, 172-176.
36. Mogensen, C. E.; Neldam, S.; Tikkanen, I.; Oren, S.; Viskoper, R.; Watts, R. W.; Cooper, M. E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 2000, 321, 1440-1444.
37. Yusuf, S.; Teo, K. K.; Pogue, J.; Dyal, L.; Copland, I.; Schumacher, H.; Dagenais, G.; Sleight, P.; Anderson, C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med., 2008, 358, 1547-1559.
38. Mann, J. F.; Schmieder, R. E.; McQueen, M.; Dyal, L.; Schumacher, H.; Pogue, J.; Wang, X.; Maggioni, A.; Budaj, A.; Chaithiraphan, S.; Dickstein, K.; Keltai, M.; Metsarinne, K.; Oto, A.; Parkhomenko, A.; Piegas, L. S.; Svendsen, T. L.; Teo, K. K.; Yusuf, S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet, 2008, 372, 547-553.
39. Brunner, H. R. Olmesartan medoxomil: Current status of its use in monotherapy. Vasc. Health Risk Manag., 2006, 2, 327-340.
40. Ikeda, H.; Hamamoto, Y.; Honjo, S.; Nabe, K.; Wada, Y.; Koshiyama, H. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res. Clin. Pract., 2008. (online)
41. Imai, E.; Ito, S.; Haneda, M.; Chan, J. C.; Makino, H. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): Rationale and study design. Hypertens. Res., 2006, 29, 703-709.
42. Appel, L. J.; Wright, J. T., Jr.; Greene, T.; Kusek, J. W.; Lewis, J. B.; Wang, X.; Lipkowitz, M. S.; Norris, K. C.; Bakris, G. L.; Rahman, M.; Contreras, G.; Rostand, S. G.; Kopple, J. D.; Gabbai, F. B.; Schulman, G. I.; Gassman, J. J.; Charleston, J.; Agodoa, L. Y. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch. Intern. Med., 2008, 168, 832-839.
43. Bryson, C. L.; Ross, H. J.; Boyko, E. J.; Young, B. A. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: Associations with diabetes and level of CKD. Am. J. Kidney Dis., 2006, 48, 720-726.
44. Jawa, A.; Nachimuthu, S.; Pendergrass, M.; Asnani, S.; Fonseca, V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J. Clin. Endocrinol. Metab., 2006, 91, 31-35.
45. Saklayen, M. G.; Gyebi, L. K.; Tasosa, J.; Yap, J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial. J. Investig. Med., 2008, 56, 714-719.
46. Ustundag, A.; Tugrul, A.; Ustundag, S.; Sut, N.; Demirkan, B. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren. Fail., 2008, 30, 982-991.
47. Han, S. Y.; Kim, C. H.; Kim, H. S.; Jee, Y. H.; Song, H. K.; Lee, M. H.; Han, K. H.; Kim, H. K.; Kang, Y. S.; Han, J. Y.; Kim, Y. S.; Cha, D. R. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol., 2006, 17, 1362-1372.
48. Fredersdorf, S.; Endemann, D. H.; Luchner, A.; Heitzmann, D.; Ulucan, C.; Birner, C.; Schmid, P.; Stoelcker, B.; Resch, M.; Muders, F.; Aj, R. G.; Weil, J. Increased Aldosterone Levels in a Model of Type 2 Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes, 2008. (in press)
49. Yoneda, T.; Takeda, Y.; Usukura, M.; Oda, N.; Takata, H.; Yamamoto, Y.; Karashima, S.; Yamagishi, M. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am. J. Hypertens., 2007, 20, 1329-1333.
50. Swaminathan, K.; Davies, J.; George, J.; Rajendra, N. S.; Morris, A. D.; Struthers, A. D. Spironolactone for poorly controlled hypertension in type 2 diabetes: Conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia, 2008, 51, 762-768.
51. Brown, M. J. Aliskiren. Circulation, 2008, 118, 773-784.
52. Jensen, C.; Herold, P.; Brunner, H. R. Aliskiren: The first renin inhibitor for clinical treatment. Nat. Rev. Drug Discov., 2008, 7, 399-410.
53. Schmieder, R. E. Renin inhibitors: Optimal strategy for renal protection. Curr. Hypertens. Rep., 2007, 9, 415-421.
54. Parving, H. H.; Persson, F.; Lewis, J. B.; Lewis, E. J.; Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med., 2008, 358, 2433-2446.
55. Chiarelli, F.; Pomilio, M.; De Luca, F. A.; Vecchiet, J.; Verrotti, A. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr. Nephrol., 2001, 16, 116-120.
56. Nguyen, G.; Danser, A. H. Prorenin and (pro)renin receptor: A review of available data from in vitro studies and experimental models in rodents. Exp. Physiol., 2008, 93, 557-563.
57. van den, H. M.; Batenburg, W. W.; Danser, A. H. Diabetic complications: A role for the prorenin-(pro)renin receptor-TGF-beta(1) axis? Mol. Cell Endocrinol., 2008. (online)
58. Feldman, D. L.; Jin, L.; Xuan, H.; Contrepas, A.; Zhou, Y.; Webb, R. L.; Mueller, D. N.; Feldt, S.; Cumin, F.; Maniara, W.; Persohn, E.; Schuetz, H.; Jan Danser, A. H.; Nguyen, G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension, 2008, 52, 130-136.
59. Feldt, S.; Maschke, U.; Dechend, R.; Luft, F. C.; Muller, D. N. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J. Am. Soc. Nephrol., 2008, 19, 743-748.
60. Ichihara, A.; Sakoda, M.; Mito-Kurauchi, A.; Itoh, H. Activated prorenin as a therapeutic target for diabetic nephropathy. Diabetes Res. Clin. Pract., 2008, 82, S63-S66.
61. Nguyen, G.; Contrepas, A. The (pro)renin receptors. J. Mol. Med., 2008, 86, 643-646.
62. Ingelfinger, J. R. Aliskiren and dual therapy in type 2 diabetes mellitus. N. Engl. J. Med., 2008, 358, 2503-2505
63. Batlle, D.; Soler, M. J.; Wysocki, J. New aspects of the renin-angiotensin system: Angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. Curr. Opin. Nephrol. Hypertens., 2008, 17, 250-257
64. Tikellis, C.; Bialkowski, K.; Pete, J.; Sheehy, K.; Su, Q.; Johnston, C.; Cooper, M. E.; Thomas, M. C. ACE2 deficiency modifies reno-protection afforded by ACE inhibition in experimental diabetes. Diabetes, 2008, 57, 1018-1025.
65. Bindom, S. M.; Lazartigues, E. The sweeter side of ACE2: Physiological evidence for a role in diabetes. Mol. Cell Endocrinol., 2008. (online)
66. Soler, M. J.; Wysocki, J.; Batlle, D. Angiotensin-converting enzyme 2 and the kidney. Exp. Physiol., 2008, 93, 549-556
67. Soler, M. J.; Wysocki, J.; Ye, M.; Lloveras, J.; Kanwar, Y.; Batlle, D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int., 2007, 72, 614-623.
68. Wong, D. W.; Oudit, G. Y.; Reich, H.; Kassiri, Z.; Zhou, J.; Liu, Q. C.; Backx, P. H.; Penninger, J. M.; Herzenberg, A. M.; Scholey, J. W. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am. J. Pathol., 2007, 171, 438-451.
69. Mizuiri, S.; Hemmi, H.; Arita, M.; Ohashi, Y.; Tanaka, Y.; Miyagi, M.; Sakai, K.; Ishikawa, Y.; Shibuya, K.; Hase, H.; Aikawa, A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis., 2008, 51, 613-623.
70. Wang, G.; Lai, F. M.; Lai, K. B.; Chow, K. M.; Kwan, C. H.; Li, K. T.; Szeto, C. C. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia, 2008, 51, 1062-1067.
71. Kakoki, M.; Takahashi, N.; Jennette, J. C.; Smithies, O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc. Natl. Acad. Sci. USA, 2004, 101, 13302-13305.
72. Riad, A.; Zhuo, J. L.; Schultheiss, H. P.; Tschope, C. The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr. Opin. Nephrol Hypertens., 2007, 16, 22-26.
73. Marceau, F.; Regoli, D. Bradykinin receptor ligands: Therapeutic perspectives. Nat. Rev. Drug Discov., 2004, 3, 845-852.
74. Phipps, J. A.; Feener, E. P. The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney. Kidney Int., 2008, 73, 1114-1119.
75. Bash, L. D.; Selvin, E.; Steffes, M.; Coresh, J.; Astor, B. C. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch. Intern. Med., 2008, 168, 2440-2447.
76. Buse, J. B.; Ginsberg, H. N.; Bakris, G. L.; Clark, N. G.; Costa, F.; Eckel, R.; Fonseca, V.; Gerstein, H. C.; Grundy, S.; Nesto, R. W.; Pignone, M. P.; Plutzky, J.; Porte, D.; Redberg, R.; Stitzel, K. F.; Stone, N. J. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 2007, 30, 162-172.
77. Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C. E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Bompoint, S.; de Galan, B. E.; Joshi, R.; Travert, F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358, 2560-2572.
78. Langham, R. G.; Kelly, D. J.; Gow, R. M.; Zhang, Y.; Cox, A. J.; Qi, W.; Thai, K.; Pollock, C. A.; Christensen, P. K.; Parving, H. H.; Gilbert, R. E. Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: Relationship to long-term glycaemic control. Diabetologia, 2008, 51, 668-674.
79. Noh, H.; King, G. L. The role of protein kinase C activation in diabetic nephropathy. Kidney Int. Suppl., 2007, (106), S49-S53.
80. Ohshiro, Y.; Ma, R. C.; Yasuda, Y.; Hiraoka-Yamamoto, J.; Clermont, A. C.; Isshiki, K.; Yagi, K.; Arikawa, E.; Kern, T. S.; King, G. L. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes, 2006, 55, 3112-3120.
81. Forbes, J. M.; Coughlan, M. T.; Cooper, M. E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes, 2008, 57, 1446-1454.
82. Anderson, P. W.; McGill, J. B.; Tuttle, K. R. Protein kinase C beta inhibition: The promise for treatment of diabetic nephropathy. Curr. Opin. Nephrol. Hypertens., 2007, 16, 397-402.
83. Tuttle, K. R.; McGill, J. B.; Haney, D. J.; Lin, T. E.; Anderson, P. W. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol., 2007, 2, 631-636.
84. Merida, I.; vila-Flores, A.; Merino, E. Diacylglycerol kinases: At the hub of cell signalling. Biochem. J., 2008, 409, 1-18.
85. Budhiraja, S.; Singh, J. Protein kinase C beta inhibitors: A new therapeutic target for diabetic nephropathy and vascular complications. Fundam. Clin. Pharmacol., 2008, 22, 231-240.
86. Coughlan, M. T.; Mibus, A. L.; Forbes, J. M. Oxidative stress and advanced glycation in diabetic nephropathy. Ann. N. Y. Acad. Sci., 2008, 1126, 190-193.
87. Su, J.; Lucchesi, P. A.; Gonzalez-Villalobos, R. A.; Palen, D. I.; Rezk, B. M.; Suzuki, Y.; Boulares, H. A.; Matrougui, K. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1432-1438.
88. Roscic, M.; Horvat, S. Transformations of bioactive peptides in the presence of sugars - characterization and stability studies of the adducts generated via the Maillard reaction. Bioorg. Med. Chem., 2006, 14, 4933-4943.
89. Yamamoto, H.; Watanabe, T.; Yamamoto, Y.; Yonekura, H.; Munesue, S.; Harashima, A.; Ooe, K.; Hossain, S.; Saito, H.; Murakami, N. RAGE in diabetic nephropathy. Curr. Mol. Med., 2007, 7, 752-757.
90. Mezzano, S.; Aros, C.; Droguett, A.; Burgos, M. E.; Ardiles, L.; Flores, C.; Schneider, H.; Ruiz-Ortega, M.; Egido, J. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial. Transplant., 2004, 19, 2505-2512.
91. Miyata, T.; Izuhara, Y. Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy? Ann. N. Y. Acad. Sci., 2008, 1126, 141-146.
92. Sourris, K. C.; Forbes, J. M.; Cooper, M. E. Therapeutic interruption of advanced glycation in diabetic nephropathy: Do all roads lead to rome? Ann. N. Y. Acad. Sci., 2008, 1126, 101-106.
93. Yamagishi, S.; Nakamura, K.; Matsui, T.; Noda, Y.; Imaizumi, T. Receptor for advanced glycation end products (RAGE): A novel therapeutic target for diabetic vascular complication. Curr. Pharm. Des., 2008, 14, 487-495.
94. Voziyan, P. A.; Hudson, B. G. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann. N. Y. Acad. Sci., 2005, 1043, 807-816.
95. Waanders, F.; van den, B. E.; Nagai, R.; van, V., I; Navis, G.; van Goor, H. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats. Nephrol Dial. Transplant., 2008, 23, 518-524.
96. Williams, M. E.; Bolton, W. K.; Khalifah, R. G.; Degenhardt, T. P.; Schotzinger, R. J.; McGill, J. B. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol., 2007, 27, 605-614
97. Chetyrkin, S. V.; Zhang, W.; Hudson, B. G.; Serianni, A. S.; Voziyan, P. A. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: Mechanism of action of pyridoxamine. Biochemistry, 2008, 47, 997-1006.
98. Khalifah, R. G.; Chen, Y.; Wassenberg, J. J. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: A rational approach to second-generation Amadorin design. Ann. N. Y. Acad. Sci., 2005, 1043, 793-806.
99. Das-Evcimen, N.; Bozdag-Dundar, O.; Sarikaya, M.; Ertan, R. In vitro aldose reductase inhibitory activity of some flavonyl-2,4-thiazolidinediones. J. Enzyme Inhib. Med. Chem., 2008, 23, 297-301.
100. Yang, B.; Hodgkinson, A.; Oates, P. J.; Millward, B. A.; Demaine, A. G. High glucose induction of DNA-binding activity of the transcription factor NFkappaB in patients with diabetic nephropathy. Biochim. Biophys. Acta, 2008, 1782, 295-302.
101. Giannoukakis, N. Drug evaluation: Ranirestat-an aldose reductase inhibitor for the potential treatment of diabetic complications. Curr. Opin. Investig. Drugs, 2006, 7, 916-923.
102. Buse, M. G. Hexosamines, insulin resistance, and the complications of diabetes: Current status. Am. J. Physiol. Endocrinol. Metab., 2006, 290, E1-E8.
103. Cheng, D. W.; Jiang, Y.; Shalev, A.; Kowluru, R.; Crook, E. D.; Singh, L. P. An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. Arch. Physiol. Biochem., 2006, 112, 189-218.
104. Weigert, C.; Friess, U.; Brodbeck, K.; Haring, H. U.; Schleicher, E. D. Glutamine:fRuctose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells. Diabetologia, 2003, 46, 852-855
105. Zheng, J. M.; Zhu, J. M.; Li, L. S.; Liu, Z. H. Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. Br. J. Pharmacol., 2008, 153, 1456-1464.
106. Gojo, A.; Utsunomiya, K.; Taniguchi, K.; Yokota, T.; Ishizawa, S.; Kanazawa, Y.; Kurata, H.; Tajima, N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol., 2007, 568, 242-247.
107. Peng, F.; Wu, D.; Gao, B.; Ingram, A. J.; Zhang, B.; Chorneyko, K.; McKenzie, R.; Krepinsky, J. C. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes, 2008, 57, 1683-1692.
108. Kikuchi, Y.; Yamada, M.; Imakiire, T.; Kushiyama, T.; Higashi, K.; Hyodo, N.; Yamamoto, K.; Oda, T.; Suzuki, S.; Miura, S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol., 2007, 192, 595-603.
109. Kolavennu, V.; Zeng, L.; Peng, H.; Wang, Y.; Danesh, F. R. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes, 2008, 57, 714-723.
110. Fornoni, A.; Ijaz, A.; Tejada, T.; Lenz, O. Role of inflammation in diabetic nephropathy. Curr. Diabetes Rev., 2008, 4, 10-17.
111. Navarro, J. F.; Mora-Fernandez, C. The role of TNF-alpha in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev., 2006, 17, 441-450.
112. Moriwaki, Y.; Inokuchi, T.; Yamamoto, A.; Ka, T.; Tsutsumi, Z.; Takahashi, S.; Yamamoto, T. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol., 2007, 44, 215-218.
113. Vieitez, P.; Gomez, O.; Uceda, E. R.; Vera, M. E.; Molina-Holgado, E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J. Renin. Angiotensin. Aldosterone. Syst., 2008, 9, 96-102.
114. DiPetrillo, K.; Gesek, F. A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am. J. Nephrol., 2004, 24, 352-359
115. Navarro, J. F.; Milena, F. J.; Mora, C.; Leon, C.; Garcia, J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am. J. Nephrol., 2006, 26, 562-570.
116. Navarro, J. F.; Mora, C.; Muros, M.; Garcia, J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J. Am. Soc. Nephrol., 2005, 16, 2119-2126
117. Rodriguez-Moran, M.; Gonzalez-Gonzalez, G.; Bermudez-Barba, M. V.; Medina de la Garza CE; Tamez-Perez, H. E.; Martinez-Martinèz, F. J.; Guerrero-Romero, F. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. Clin. Nephrol., 2006, 66, 3-10.
118. Pacher, P.; Szabo, C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. Antioxid. Redox. Signal., 2005, 7, 1568-1580.
119. Szabo, C.; Biser, A.; Benko, R.; Bottinger, E.; Susztak, K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes, 2006, 55, 3004-3012.
120. Savoia, C.; Schiffrin, E. L. Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin. Sci. (Lond.), 2007, 112, 375-384.
121. Schmid, H.; Boucherot, A.; Yasuda, Y.; Henger, A.; Brunner, B.; Eichinger, F.; Nitsche, A.; Kiss, E.; Bleich, M.; Grone, H. J.; Nelson, P. J.; Schlondorff, D.; Cohen, C. D.; Kretzler, M. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes, 2006, 55, 2993-3003.
122. Mizuno, M.; Sada, T.; Kato, M.; Fukushima, Y.; Terashima, H.; Koike, H. The effect of angiotensin II receptor blockade on an endstage renal failure model of type 2 diabetes. J. Cardiovasc. Pharmacol., 2006, 48, 135-142.
123. Gruden, G.; Setti, G.; Hayward, A.; Sugden, D.; Duggan, S.; Burt, D.; Buckingham, R. E.; Gnudi, L.; Viberti, G. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: Inhibition by rosiglitazone. J. Am. Soc. Nephrol., 2005, 16, 688-696.
124. Ohga, S.; Shikata, K.; Yozai, K.; Okada, S.; Ogawa, D.; Usui, H.; Wada, J.; Shikata, Y.; Makino, H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal Physiol., 2007, 292, F1141-F1150.
125. Park, C. W.; Kim, H. W.; Ko, S. H.; Lim, J. H.; Ryu, G. R.; Chung, H. W.; Han, S. W.; Shin, S. J.; Bang, B. K.; Breyer, M. D.; Chang, Y. S. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J. Am. Soc. Nephrol., 2007, 18, 1227-1238.
126. Goicoechea, M.; de Vinuesa, S. G.; Lahera, V.; Cachofeiro, V.; Gomez-Campdera, F.; Vega, A.; Abad, S.; Luno, J. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J. Am. Soc. Nephrol., 2006, 17, S231-S235.
127. Matsumoto, M.; Tanimoto, M.; Gohda, T.; Aoki, T.; Murakoshi, M.; Yamada, K.; Yamazaki, T.; Kaneko, S.; Horikoshi, S.; Tomino, Y. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism, 2008, 57, 691-697.
128. Wu, Y. G.; Lin, H.; Qian, H.; Zhao, M.; Qi, X. M.; Wu, G. Z.; Lin, S. T. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm. Res., 2006, 55, 192-199.
129. Kanamori, H.; Matsubara, T.; Mima, A.; Sumi, E.; Nagai, K.; Takahashi, T.; Abe, H.; Iehara, N.; Fukatsu, A.; Okamoto, H.; Kita, T.; Doi, T.; Arai, H. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem. Biophys. Res. Commun., 2007, 360, 772-777.
130. Ninichuk, V.; Khandoga, A. G.; Segerer, S.; Loetscher, P.; Schlapbach, A.; Revesz, L.; Feifel, R.; Khandoga, A.; Krombach, F.; Nelson, P. J.; Schlondorff, D.; Anders, H. J. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am. J. Pathol., 2007, 170, 1267-1276.
131. Qiu-Yue, W.; Fen-Qin, C. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in Type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 2008. (online)
132. Tesch, G. H. MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal. Physiol., 2008, 294, F697-F701.
133. Obligado, S. H.; Ibraghimov-Beskrovnaya, O.; Zuk, A.; Meijer, L.; Nelson, P. J. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int., 2008, 73, 684-690.
134. Rosenberger, C.; Khamaisi, M.; Abassi, Z.; Shilo, V.; Weksler-zangen, ]S.; Goldfarb, M.; Shina, A.; Zibertrest, F.; Eckardt, K. U.; Rosen, S.; Heyman, S. N. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int., 2008, 73, 34-42.
135. Ohtomo, S.; Nangaku, M.; Izuhara, Y.; Takizawa, S.; Strihou, C. Y.; Miyata, T. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol. Dial. Transplant., 2008, 23, 1166-1172.
136. Petersen, M.; Thorikay, M.; Deckers, M.; van, D. M.; Grygielko, E. T.; Gellibert, F.; de Gouville, A. C.; Huet, S.; ten, D. P.; Laping, N. J. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int., 2008, 73, 705-715.
137. Perico, N.; Remuzzi, G. Inhibition of TGF-beta expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney Int., 2007, 72, 1419-1421.
138. Woo, V.; Ni, L. S.; Hak, D.; Berard, L.; Zhu, F.; Khan, S.; Ma, G. M.; Penner, B.; Shen, G. X. Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. Clin. Invest. Med., 2006, 29, 365-372.
139. Yung, S.; Lee, C. Y.; Zhang, Q.; Lau, S. K.; Tsang, R. C.; Chan, T. M. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol. Dial. Transplant., 2006, 21, 1504-1513.
140. Daniel, C.; Schaub, K.; Amann, K.; Lawler, J.; Hugo, C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes, 2007, 56, 2982-2989.
141. Chen, S.; Ziyadeh, F. N. Vascular endothelial growth factor and diabetic nephropathy. Curr. Diab. Rep., 2008, 8, 470-476
142. Liu, E.; Morimoto, M.; Kitajima, S.; Koike, T.; Yu, Y.; Shiiki, H.; Nagata, M.; Watanabe, T.; Fan, J. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J. Am. Soc. Nephrol., 2007, 18, 2094-2104.
143. Ziyadeh, F. N.; Wolf, G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev., 2008, 4, 39-45.
144. Nakagawa, T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: An explanation for the paradoxical effects of VEGF in renal disease. Am. J. Physiol. Renal. Physiol., 2007, 292, F1665-F1672.
145. Sung, S. H.; Ziyadeh, F. N.; Wang, A.; Pyagay, P. E.; Kanwar, Y. S.; Chen, S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol., 2006, 17, 3093-3104.
146. Kelly, D. J.; Buck, D.; Cox, A. J.; Zhang, Y.; Gilbert, R. E. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am. J. Physiol. Renal. Physiol., 2007, 293, F565-F574.
147. Advani, A.; Kelly, D. J.; Advani, S. L.; Cox, A. J.; Thai, K.; Zhang, Y.; White, K. E.; Gow, R. M.; Marshall, S. M.; Steer, B. M.; Marsden, P. A.; Rakoczy, P. E.; Gilbert, R. E. Role of VEGF in maintaining renal
148. Eremina, V.; Baelde, H. J.; Quaggin, S. E. Role of the VEGF - a signaling pathway in the glomerulus: Evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol., 2007, 106, 32-37.
149. Yokoi, H.; Mukoyama, M.; Mori, K.; Kasahara, M.; Suganami, T.; Sawai, K.; Yoshioka, T.; Saito, Y.; Ogawa, Y.; Kuwabara, T.; Sugawara, A.; Nakao, K. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int., 2008, 73, 446-455.
150. Burns, W. C.; Twigg, S. M.; Forbes, J. M.; Pete, J.; Tikellis, C.; Thallas-Bonke, V.; Thomas, M. C.; Cooper, M. E.; Kantharidis, P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J. Am. Soc. Nephrol., 2006, 17, 2484-2494.
151. Wahab, N.; Cox, D.; Witherden, A.; Mason, R. M. Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1). Biochem. J., 2007, 406, 131-138.
152. Nguyen, T. Q.; Tarnow, L.; Jorsal, A.; Oliver, N.; Roestenberg, P.; Ito, Y.; Parving, H. H.; Rossing, P.; van Nieuwenhoven, F. A.; Goldschmeding, R. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care, 2008, 31, 1177-1182.
153. Ren, X.; Guan, G.; Liu, G.; Liu, G. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats. Pharmacology, 2008, 83, 80-87.
154. Uehara, G.; Suzuki, D.; Toyoda, M.; Umezono, T.; Sakai, H. Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy. Clin. Exp. Nephrol., 2004, 8, 36-42.
155. ] Vasylyeva, T. L.; Ferry, R. J., Jr. Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res. Clin. Pract., 2007, 76, 177-186.
156. Sarafidis, P. A.; Ruilope, L. M. Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications. Am. J. Nephrol., 2006, 26, 232-244.
157. Hovind, P.; Lamberts, S.; Hop, W.; Deinum, J.; Tarnow, L.; Parving, H. H.; Janssen, J. A. An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. Eur. J. Endocrinol., 2007, 156, 83-90.
158. McLennan, S. V.; Kelly, D. J.; Schache, M.; Waltham, M.; Dy, V.; Langham, R. G.; Yue, D. K.; Gilbert, R. E. Advanced glycation end products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy? Kidney Int., 2007, 72, 481-488.
159. Rysz, J.; Banach, M.; Stolarek, R. A.; Pasnik, J.; Cialkowska-Rysz, A.; Koktysz, R.; Piechota, M.; Baj, Z. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J. Nephrol., 2007, 20, 444-452.
160. Thrailkill, K. M.; Clay, B. R.; Fowlkes, J. L. Matrix metalloproteinases: Their potential role in the pathogenesis of diabetic nephropathy. Endocrine, 2008. (online)
161. Han, S. Y.; Jee, Y. H.; Han, K. H.; Kang, Y. S.; Kim, H. K.; Han, J. Y.; Kim, Y. S.; Cha, D. R. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol. Dial. Transplant., 2006, 21, 2406-2416.
162. Derosa, G.; D'Angelo, A.; Scalise, F.; Avanzini, M. A.; Tinelli, C.; Peros, E.; Fogari, E.; Cicero, A. F. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007, 22, 361-370.
163. Pavenstadt, H.; Kriz, W.; Kretzler, M. Cell biology of the glomerular podocyte. Physiol. Rev., 2003, 83, 253-307.
164. Durvasula, R. V.; Shankland, S. J. Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal Physiol., 2008, 294, F830-F839.
165. Li, J. J.; Kwak, S. J.; Jung, D. S.; Kim, J. J.; Yoo, T. H.; Ryu, D. R.; Han, S. H.; Choi, H. Y.; Lee, J. E.; Moon, S. J.; Kim, D. K.; Han, D. S.; Kang, S. W. Podocyte biology in diabetic nephropathy. Kidney Int. Suppl., 2007, (106), S36-S42.
166. Marshall, S. M. The podocyte: A potential therapeutic target in diabetic nephropathy? Curr. Pharm. Des., 2007, 13, 2713-2720.
167. Han, S. H.; Yang, S.; Jung, D. S.; Li, J. J.; Kim, J. J.; Kwak, S. J.; Kim, D. K.; Moon, S. J.; Lee, J. E.; Han, D. S.; Kang, S. W. Gene expression patterns in glucose-stimulated podocytes. Biochem. Biophys. Res. Commun., 2008, 370, 514-518.
168. Susztak, K.; Raff, A. C.; Schiffer, M.; Bottinger, E. P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes, 2006, 55, 225-233.
169. Wolf, G.; Ziyadeh, F. N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol., 2007, 106, 26-31.
170. Chuang, P. Y.; Yu, Q.; Fang, W.; Uribarri, J.; He, J. C. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int., 2007, 72, 965-976.
171. Nishiyama, A.; Nakagawa, T.; Kobori, H.; Nagai, Y.; Okada, N.; Konishi, Y.; Morikawa, T.; Okumura, M.; Meda, I.; Kiyomoto, H.; Hosomi, N.; Mori, T.; Ito, S.; Imanishi, M. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J. Hypertens., 2008, 26, 1849-1859.
172. Reiser, J.; Mundel, P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr. Hypertens. Rep., 2007, 9, 403-408.
173. Weiss, R.; Niecestro, R.; Raz, I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs, 2007, 67, 2681-2696.
174. Heerspink, H. L.; Greene, T.; Lewis, J. B.; Raz, I.; Rohde, R. D.; Hunsicker, L. G.; Schwartz, S. L.; Aronoff, S.; Katz, M. A.; Eisner, G. M.; Mersey, J. H.; Wiegmann, T. B. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol. Dial. Transplant., 2008, 23, 1946-1954.
175. Lambers Heerspink, H. J.; Fowler, M. J.; Volgi, J.; Reutens, A. T.; Klein, I.; Herskovits, T. A.; Packham, D. K.; Fraser, I. R.; Schwartz, S. L.; Abaterusso, C.; Lewis, J. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet. Med., 2007, 24, 1290-1295.
176. Awad, A. S.; Rouse, M.; Liu, L.; Vergis, A. L.; Rosin, D. L.; Linden, J.; Sedor, J. R.; Okusa, M. D. Activation of adenosine 2A receptors preserves structure and function of podocytes. J. Am. Soc. Nephrol., 2008, 19, 59-68.
177. Faulhaber-Walter, R.; Chen, L.; Oppermann, M.; Kim, S. M.; Huang, Y.; Hiramatsu, N.; Mizel, D.; Kajiyama, H.; Zerfas, P.; Briggs, J. P.; Kopp, J. B.; Schnermann, J. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J. Am. Soc. Nephrol., 2008, 19, 722-730.
178. Kim, J. J.; Li, J. J.; Jung, D. S.; Kwak, S. J.; Ryu, D. R.; Yoo, T. H.; Han, S. H.; Choi, H. Y.; Kim, H. J.; Han, D. S.; Kang, S. W. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J. Am. Soc. Nephrol., 2007, 18, 2303-2310.
179. Toyoda, M.; Suzuki, D.; Umezono, T.; Uehara, G.; Maruyama, M.; Honma, M.; Sakai, T.; Sakai, H. Expression of human nephrin mRNA in diabetic nephropathy. Nephrol. Dial. Transplant., 2004, 19, 380-385.
180. Amazonas, R. B.; Sanita, R. A.; Kawachi, H.; de Faria, J. B. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus. Nephron Physiol., 2007, 107, 57-64.
181. Menne, J.; Meier, M.; Park, J. K.; Boehne, M.; Kirsch, T.; Lindschau, C.; Ociepka, R.; Leitges, M.; Rinta-Valkama, J.; Holthofer, H.; Haller, H. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int., 2006, 70, 1456-1462.
182. Gilbert, R. E.; Marsden, P. A. Activated protein C and diabetic nephropathy. N. Engl. J. Med., 2008, 358, 1628-1630.
183. Isermann, B.; Vinnikov, I. A.; Madhusudhan, T.; Herzog, S.; Kashif, M.; Blautzik, J.; Corat, M. A.; Zeier, M.; Blessing, E.; Oh, J.; Gerlitz, B.; Berg, D. T.; Grinnell, B. W.; Chavakis, T.; Esmon, C. T.; Weiler, H.; Bierhaus, A.; Nawroth, P. P. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat. Med., 2007, 13, 1349-1358.
184. Yilmaz, M. I.; Saglam, M.; Qureshi, A. R.; Carrero, J. J.; Caglar, K.; Eyileten, T.; Sonmez, A.; Cakir, E.; Oguz, Y.; Vural, A.; Yenicesu, M.; Stenvinkel, P.; Lindholm, B.; Axelsson, J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial. Transplant., 2008, 23, 1621-1627.
185. Ahima, R. S. Linking adiponectin to proteinuria. J Clin Invest 2008, 118, 1619-1622.
186. Sharma, K.; Ramachandrarao, S.; Qiu, G.; Usui, H. K.; Zhu, Y.; Dunn, S. R.; Ouedraogo, R.; Hough, K.; McCue, P.; Chan, L.; Falkner, B.; Goldstein, B. J. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest., 2008, 118, 1645-1656
187. Axelsson, J.; Bergsten, A.; Qureshi, A. R.; Heimburger, O.; Barany, P.; Lonnqvist, F.; Lindholm, B.; Nordfors, L.; Alvestrand, A.; Stenvinkel, P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int., 2006, 69, 596-604.
188. Osawa, H.; Ochi, M.; Kato, K.; Yamauchi, J.; Nishida, W.; Takata, Y.; Kawamura, R.; Onuma, H.; Takasuka, T.; Shimizu, I.; Fujii, Y.; Ohashi, J.; Makino, H. Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochem. Biophys. Res. Commun., 2007, 355, 342-346.
189. Yilmaz, M. I.; Saglam, M.; Carrero, J. J.; Qureshi, A. R.; Caglar, K.; Eyileten, T.; Sonmez, A.; Cakir, E.; Yenicesu, M.; Lindholm, B.; Stenvinkel, P.; Axelsson, J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant., 2008, 23, 959-965.
190. Hills, C. E.; Al-Rasheed, N.; Al-Rasheed, N.; Willars, G. B.; Brunskill, N. J. C-Peptide reverses TGF-{beta}1-Induced changes in Renal Proximal Tubular Cells: Implications for the treatment of Diabetic Nephropathy. Am. J. Physiol. Renal Physiol., 2008. (online)
191. Maezawa, Y.; Yokote, K.; Sonezaki, K.; Fujimoto, M.; Kobayashi, K.; Kawamura, H.; Tokuyama, T.; Takemoto, M.; Ueda, S.; Kuwaki, T.; Mori, S.; Wahren, J.; Saito, Y. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab. Res. Rev., 2006, 22, 313-322.
192. Rebsomen, L.; Pitel, S.; Boubred, F.; Buffat, C.; Feuerstein, J. M.; Raccah, D.; Vague, P.; Tsimaratos, M. C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab., 2006, 32, 223-228.
193. Rebsomen, L.; Khammar, A.; Raccah, D.; Tsimaratos, M. C-Peptide effects on renal physiology and diabetes. Exp. Diabetes Res., 2008, 2008, 281536. (online)
194. Granier, C.; Makni, K.; Molina, L.; Jardin-Watelet, B.; Ayadi, H.; Jarraya, F. Gene and protein markers of diabetic nephropathy. Nephrol. Dial. Transplant., 2008, 23, 792-799.
195. Middleton, R. J.; Foley, R. N.; Hegarty, J.; Cheung, C. M.; McElduff, P.; Gibson, J. M.; Kalra, P. A.; O'Donoghue, D. J.; New, J. P. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol. Dial. Transplant., 2006, 21, 88-92.
196. Vassalotti, J. A.; Stevens, L. A.; Levey, A. S. Testing for chronic kidney disease: A position statement from the National Kidney Foundation. Am. J. Kidney Dis., 2007, 50, 169-180
197. So, W. Y.; Kong, A. P.; Ma, R. C.; Ozaki, R.; Szeto, C. C.; Chan, N. N.; Ng, V.; Ho, C. S.; Lam, C. W.; Chow, C. C.; Cockram, C. S.; Chan, J. C.; Tong, P. C. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care, 2006, 29, 2046-2052.
198. Zandbergen, A. A.; Sijbrands, E. J.; Lamberts, S. W.; Bootsma, A. H. Normotensive women with type 2 diabetes and microalbuminuria are at high risk for macrovascular disease. Diabetes Care, 2006, 29, 1851-1855.
199. Jaar, B. G.; Khatib, R.; Plantinga, L.; Boulware, L. E.; Powe, N. R. Principles of screening for chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2008, 3, 601-609.
200. Araki, S.; Haneda, M.; Koya, D.; Hidaka, H.; Sugimoto, T.; Isono, M.; Isshiki, K.; Chin-Kanasaki, M.; Uzu, T.; Kashiwagi, A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes, 2007, 56, 1727-1730.
201. Eijkelkamp, W. B.; Zhang, Z.; Remuzzi, G.; Parving, H. H.; Cooper, M. E.; Keane, W. F.; Shahinfar, S.; Gleim, G. W.; Weir, M. R.; Brenner, B. M.; de Zeeuw, D. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol., 2007, 18, 1540-1546.
202. Ibsen, H.; Olsen, M. H.; Wachtell, K.; Borch-Johnsen, K.; Lindholm, L. H.; Mogensen, C. E. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J. Nephrol., 2008, 21, 566-569.
203. Cirillo, M.; Lanti, M. P.; Menotti, A.; Laurenzi, M.; Mancini, M.; Zanchetti, A.; De Santo, N. G. Definition of kidney dysfunction as a cardiovascular risk factor: Use of urinary albumin excretion and estimated glomerular filtration rate. Arch. Intern. Med., 2008, 168, 617-624.
204. Foster, M. C.; Hwang, S. J.; Larson, M. G.; Parikh, N. I.; Meigs, J. B.; Vasan, R. S.; Wang, T. J.; Levy, D.; Fox, C. S. Cross-classification of microalbuminuria and reduced glomerular filtration rate: Associations between cardiovascular disease risk factors and clinical outcomes. Arch. Intern. Med., 2007, 167, 1386-1392.
205. Merchant, M. L.; Klein, J. B. Proteomics and diabetic nephropathy. Semin. Nephrol., 2007, 27, 627-636.
206. St Clair, L.; Ballantyne, C. M. Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am. J. Cardiol., 2007, 99, 80B-88B.
207. Yoshida, S. I.; Hashimoto, T.; Kihara, M.; Imai, N.; Yasuzaki, H.; Nomura, K.; Kiuchi, Y.; Tamura, K.; Ishigami, T.; Hirawa, N.; Toya, Y.; Kitamura, H.; Umemura, S. Urinary Oxidative Stress Markers Closely Reflect the Efficacy of Candesartan Treatment for Diabetic Nephropathy. Nephron Exp. Nephrol., 2008, 111, e20-e30.
208. Mima, A.; Arai, H.; Matsubara, T.; Abe, H.; Nagai, K.; Tamura, Y.; Torikoshi, K.; Araki, M.; Kanamori, H.; Takahashi, T.; Tominaga, T.; Matsuura, M.; Iehara, N.; Fukatsu, A.; Kita, T.; Doi, T. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Diabetes, 2008, 57, 1712-1722.
209. Otu, H. H.; Can, H.; Spentzos, D.; Nelson, R. G.; Hanson, R. L.; Looker, H. C.; Knowler, W. C.; Monroy, M.; Libermann, T. A.; Karumanchi, S. A.; Thadhani, R. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care, 2007, 30, 638-643.
210. Prig ent, A. Monitoring renal function and limitations of renal function tests. Semin. Nucl. Med., 2008, 38, 32-46.
211. Jerums, G.; Premaratne, E.; Panagiotopoulos, S.; Clarke, S.; Power, D. A.; MacIsaac, R. J. New and old markers of progression of diabetic nephropathy. Diabetes Res. Clin. Pract., 2008, 82, S30-S37.
212. Yang, Y. S.; Peng, C. H.; Lin, C. K.; Wang, C. P.; Huang, C. N. Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes. Intern. Med., 2007, 46, 801-806.
213. Hojs, R.; Bevc, S.; Ekart, R.; Gorenjak, M.; Puklavec, L. Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease. Ren. Fail., 2008, 30, 181-186.
214. Premaratne, E.; MacIsaac, R. J.; Finch, S.; Panagiotopoulos, S.; Ekinci, E.; Jerums, G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care, 2008, 31, 971-973.
215. Stevens, L. A.; Coresh, J.; Schmid, C. H.; Feldman, H. I.; Froissart, M.; Kusek, J.; Rossert, J.; Van Lente, F.; Bruce, R. D., III; Zhang, Y. L.; Greene, T.; Levey, A. S. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis., 2008, 51, 395-406.
216. Pucci, L.; Triscornia, S.; Lucchesi, D.; Fotino, C.; Pellegrini, G.; Pardini, E.; Miccoli, R.; Del Prato, S.; Penno, G. Cystatin C and estimates of renal function: Searching for a better measure of kidney function in diabetic patients. Clin. Chem., 2007, 53, 480-488.
217. Willems, D.; Wolff, F.; Mekhali, F.; Gillet, C. Cystatin C for early detection of renal impairment in diabetes. Clin. Biochem., 2009, 42, 108-110.
218. Deo, R.; Fyr, C. L.; Fried, L. F.; Newman, A. B.; Harris, T. B.; Angleman, S.; Green, C.; Kritchevsky, S. B.; Chertow, G. M.; Cummings, S. R.; Shlipak, M. G. Kidney dysfunction and fatal cardiovascular disease-an association independent of atherosclerotic events: Results from the Health, Aging, and Body Composition (Health ABC) study. Am. Heart J., 2008, 155, 62-68.
219. Shlipak, M. G.; Sarnak, M. J.; Katz, R.; Fried, L. F.; Seliger, S. L.; Newman, A. B.; Siscovick, D. S.; Stehman-Breen, C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med., 2005, 352, 2049-2060.
220. Wang, J.; Sim, A. S.; Wang, X. L.; Salonikas, C.; Moriatis, M.; Naidoo, D.; Wilcken, D. E. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis, 2008, 197, 853-859.
221. Kottgen, A.; Selvin, E.; Stevens, L. A.; Levey, A. S.; Van Lente, F.; Coresh, J. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis., 2008, 51, 385-394.
222. Shlipak, M. G.; Katz, R.; Sarnak, M. J.; Fried, L. F.; Newman, A. B.; Stehman-Breen, C.; Seliger, S. L.; Kestenbaum, B.; Psaty, B.; Tracy, R. P.; Siscovick, D. S. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern. Med., 2006, 145, 237-246.
223. Zethelius, B.; Berglund, L.; Sundstrom, J.; Ingelsson, E.; Basu, S.; Larsson, A.; Venge, P.; Arnlov, J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med., 2008, 358, 2107-2116.
224. Almdal, T.; Scharling, H.; Jensen, J. S.; Vestergaard, H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch. Intern. Med., 2004, 164, 1422-1426.
225. Boden-Albala, B.; Cammack, S.; Chong, J.; Wang, C.; Wright, C.; Rundek, T.; Elkind, M. S. V.; Paik, M. C.; Sacco, R. L. Diabetes, Fasting Glucose Levels, and Risk of Ischemic Stroke and Vascular Events: Findings from the Northern Manhattan Study (NOMAS). Diabetes Care, 2008, 31, 1132-1137.
226. Khatri, M.; Wright, C. B.; Nickolas, T. L.; Yoshita, M.; Paik, M. C.; Kranwinkel, G.; Sacco, R. L.; DeCarli, C. Chronic kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan Study (NOMAS). Stroke, 2007, 38, 3121-3126.
227. Kim, J. A.; Montagnani, M.; Koh, K. K.; Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 2006, 113, 1888-1904.
228. Stam, F.; van Guldener, C.; Schalkwijk, C. G.; ter Wee, P. M.; Donker, A. J.; Stehouwer, C. D. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol. Dial. Transplant., 2003, 18, 892-898.
229. Stam, F.; van Guldener, C.; Becker, A.; Dekker, J. M.; Heine, R. J.; Bouter, L. M.; Stehouwer, C. D. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn study. J. Am. Soc. Nephrol., 2006, 17, 537-545.
230. Schmieder, R. E.; Delles, C.; Mimran, A.; Fauvel, J. P.; Ruilope, L. M. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care, 2007, 30, 1351-1356.
231. Cortes-Sanabria, L.; Cabrera-Pivaral, C. E.; Cueto-Manzano, A. M.; Rojas-Campos, E.; Barragan, G.; Hernandez-Anaya, M.; Martinez-Ramirez, H. R. Improving care of patients with diabetes and CKD: A pilot study for a cluster-randomized trial. Am. J. Kidney Dis., 2008, 51, 777-788.
232. Phisitkul, K.; Hegazy, K.; Chuahirun, T.; Hudson, C.; Simoni, J.; Rajab, H.; Wesson, D. E. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am. J. Med. Sci., 2008, 335, 284-291.
233. Rossi, M. C.; Nicolucci, A.; Pellegrini, F.; Comaschi, M.; Ceriello, A.; Cucinotta, D.; Giorda, C.; Valentini, U.; Vespasiani, G.; De Cosmo, S. Identifying patients with type 2 diabetes at high risk of microalbuminuria: Results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrol. Dial. Transplant., 2008, 23, 1278-1284.
234. Seyahi, N.; Kahveci, A.; Bolayirli, M.; Akman, C.; Altiparmak, M. R.; Apaydin, S.; Ataman, R.; Sariyar, M.; Serdengecti, K.; Erek, E. Coronary artery calcification and chronically decreased GFR in living kidney donors. Am. J. Kidney Dis., 2007, 49, 143-152.
235. Anand, D. V.; Lim, E.; Darko, D.; Bassett, P.; Hopkins, D.; Lipkin, D.; Corder, R.; Lahiri, A. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J. Am. Coll. Cardiol., 2007, 50, 2218-2225.
236. Ix, J. H.; Katz, R.; Kestenbaum, B.; Fried, L. F.; Kramer, H.; Stehman-Breen, C.; Shlipak, M. G. Association of mild to moderate kidney dysfunction and coronary calcification. J. Am. Soc. Nephrol., 2008, 19, 579-585.
237. Mehrotra, R.; Budoff, M.; Hokanson, J. E.; Ipp, E.; Takasu, J.; Adler, S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int., 2005, 68, 1258-1266.
238. Textor, S. C. Atherosclerotic renal artery stenosis: Overtreated but underrated? J. Am. Soc. Nephrol., 2008, 19, 656-659.
239. Silva, J. A. Evaluation and approach to treatment of renal artery stenosis in patients with diabetic nephropathy. Curr. Diabetes Rep., 2008, 8, 494-498.
240. Potter, K.; Hankey, G. J.; Green, D. J.; Eikelboom, J. W.; Arnolda, L. F. Homocysteine or renal impairment: Which is the real cardiovascular risk factor? Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1158-1164.
241. Mtiraoui, N.; Ezzidi, I.; Chaieb, M.; Marmouche, H.; Aouni, Z.; Chaieb, A.; Mahjoub, T.; Vaxillaire, M.; Almawi, W. Y. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res. Clin. Pract., 2007, 75, 99-106.
242. Zintzaras, E.; Uhlig, K.; Koukoulis, G. N.; Papathanasiou, A. A.; Stefanidis, I. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: A meta-analysis. J. Hum. Genet., 2007, 52, 881-890.
243. Kanetsuna, Y.; Takahashi, K.; Nagata, M.; Gannon, M. A.; Breyer, M. D.; Harris, R. C.; Takahashi, T. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am. J. Pathol., 2007, 170, 1473-1484.
244. Mohan, S.; Reddick, R. L.; Musi, N.; Horn, D. A.; Yan, B.; Prihoda, T. J.; Natarajan, M.; bboud-Werner, S. L. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab. Invest., 2008, 88, 515-528.
245. Nakagawa, T.; Sato, W.; Glushakova, O.; Heinig, M.; Clarke, T.; Campbell-Thompson, M.; Yuzawa, Y.; Atkinson, M. A.; Johnson, R. J.; Croker, B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol., 2007, 18, 539-550.
246. Hohenstein, B.; Hugo, C. P.; Hausknecht, B.; Boehmer, K. P.; Riess, R. H.; Schmieder, R. E. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol. Dial. Transplant., 2008, 23, 1346-1354.
247. Prabhakar, S. S. Pathogenic role of nitric oxide alterations in diabetic nephropathy. Curr. Diab. Rep., 2005, 5, 449-454
248. Astrup, A. S.; Tarnow, L.; Pietraszek, L.; Schalkwijk, C. G.; Stehouwer, C. D.; Parving, H. H.; Rossing, P. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: Association with mortality and decline of glomerular filtration rate. Diabetes Care, 2008, 31, 1170-1176.
249. Balakumar, P.; Chakkarwar, V. A.; Krishan, P.; Singh, M. Vascular endothelial dysfunction: A tug of war in diabetic nephropathy? Biomed. Pharmacother., 2008. (online)
250. Persson, F.; Rossing, P.; Hovind, P.; Stehouwer, C. D.; Schalkwijk, C. G.; Tarnow, L.; Parving, H. H. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand. J. Clin. Lab. Invest., 2008, 68, 731-738.
251. Lajer, M.; Tarnow, L.; Jorsal, A.; Teerlink, T.; Parving, H. H.; Rossing, P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 2008, 31, 747-752.
252. Ueda, S.; Yamagishi, S.; Matsumoto, Y.; Fukami, K.; Okuda, S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp. Nephrol., 2007, 11, 115-121.
253. Leong, T.; Zylberstein, D.; Graham, I.; Lissner, L.; Ward, D.; Fogarty, J.; Bengtsson, C.; Bjorkelund, C.; Thelle, D. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 961-967.
254. Dursun, B.; Dursun, E.; Capraz, I.; Ozben, T.; Apaydin, A.; Suleymanlar, G. Are uremia, diabetes, and atherosclerosis linked with impaired antioxidant mechanisms? J. Investig. Med., 2008, 56, 545-552.
255. Tan, A. L.; Forbes, J. M.; Cooper, M. E. AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol., 2007, 27, 130-143
256. Shibata, R.; Ueda, S.; Yamagishi, S. I.; Kaida, Y.; Matsumoto, Y.; Fukami, K.; Hayashida, A.; Matsuoka, H.; Kato, S.; Kimoto, M.; Okuda, S. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol. Dial. Transplant., 2008. (online)
257. Singh, J. P. Dimethylarginine dimethylaminohydrolase: A new therapeutic target for the modulation of nitric oxide and angiogenesis. Curr. Opin. Investig. Drugs, 2007, 8, 736-741.
258. Thallas-Bonke, V.; Thorpe, S. R.; Coughlan, M. T.; Fukami, K.; Yap, F. Y.; Sourris, K. C.; Penfold, S. A.; Bach, L. A.; Cooper, M. E.; Forbes, J. M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes, 2008, 57, 460-469.
259. Lambeth, J. D.; Krause, K. H.; Clark, R. A. NOX enzymes as novel targets for drug development. Semin. Immunopathol., 2008, 30, 339-363.
260. Paravicini, T. M.; Touyz, R. M. NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities. Diabetes Care, 2008, 31, S170-S180.
261. Abdul-Ghani, M. A.; DeFronzo, R. A. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr. Diab. Rep., 2008, 8, 173-178.
262. Rosca, M. G.; Mustata, T. G.; Kinter, M. T.; Ozdemir, A. M.; Kern, T. S.; Szweda, L. I.; Brownlee, M.; Monnier, V. M.; Weiss, M. F. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Renal. Physiol., 2005, 289, F420-F430.
263. Gong, D.; Lu, J.; Chen, X.; Choong, S. Y.; Zhang, S.; Chan, Y. K.; Glyn-Jones, S.; Gamble, G. D.; Phillips, A. R.; Cooper, G. J. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats. Mol. Pharmacol., 2006, 70, 2045-2051.
264. Ito, S.; Fujita, H.; Narita, T.; Yaginuma, T.; Kawarada, Y.; Kawagoe, M.; Sugiyama, T. Urinary copper excretion in type 2 diabetic patients with nephropathy. Nephron, 2001, 88, 307-312.
265. Gong, D.; Lu, J.; Chen, X.; Reddy, S.; Crossman, D. J.; Glyn-Jones, S.; Choong, Y. S.; Kennedy, J.; Barry, B.; Zhang, S.; Chan, Y. K.; Ruggiero, K.; Phillips, A. R.; Cooper, G. J. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia, 2008, 51, 1741-1751.
266. Lu, J.; Chan, Y. K.; Gamble, G. D.; Poppitt, S. D.; Othman, A. A.; Cooper, G. J. Triethylenetetramine and metabolites: Levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. Drug Metab. Dispos., 2007, 35, 221-227.
267. Al Kateb, H.; Boright, A. P.; Mirea, L.; Xie, X.; Sutradhar, R.; Mowjoodi, A.; Bharaj, B.; Liu, M.; Bucksa, J. M.; Arends, V. L.; Steffes, M. W.; Cleary, P. A.; Sun, W.; Lachin, J. M.; Thorner, P. S.; Ho, M.; McKnight, A. J.; Maxwell, A. P.; Savage, D. A.; Kidd, K. K.; Kidd, J. R.; Speed, W. C.; Orchard, T. J.; Miller, R. G.; Sun, L.; Bull, S. B.; Paterson, A. D. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes, 2008, 57, 218-228.
268. Duann, P.; Datta, P. K.; Pan, C.; Blumberg, J. B.; Sharma, M.; Lianos, E. A. Superoxide dismutase mimetic preserves the glomerular capillary permeability barrier to protein. J. Pharmacol. Exp. Ther., 2006, 316, 1249-1254.
269. Hocher, B.; Schwarz, A.; Reinbacher, D.; Jacobi, J.; Lun, A.; Priem, F.; Bauer, C.; Neumayer, H. H.; Raschack, M. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron, 2001, 87, 161-169.
270. Sasser, J. M.; Sullivan, J. C.; Hobbs, J. L.; Yamamoto, T.; Pollock, D. M.; Carmines, P. K.; Pollock, J. S. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol., 2007, 18, 143-154.
271. Zhu, Y. C.; Zhu, Y. Z.; Moore, P. K. The role of urotensin II in cardiovascular and renal physiology and diseases. Br. J. Pharmacol., 2006, 148, 884-901.
272. Sidharta, P. N.; Wagner, F. D.; Bohnemeier, H.; Jungnik, A.; Halabi, A.; Krahenbuhl, S.; Chadha-Boreham, H.; Dingemanse, J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin. Pharmacol. Ther., 2006, 80, 246-256.
273. Li, X.; Hu, J.; Zhang, R.; Sun, X.; Zhang, Q.; Guan, X.; Chen, J.; Zhu, Q.; Li, S. Urocortin ameliorates diabetic nephropathy in obese db/db mice. Br. J. Pharmacol., 2008, 154, 1025-1034.
274. Agnani, S.; Vachharajani, V. T.; Gupta, R.; Atray, N. K.; Vachharajani, T. J. Does treating obesity stabilize chronic kidney disease? BMC Nephrol., 2005, 6, 7.
275. Hsu, C. y.; McCulloch, C. E.; Iribarren, C.; Darbinian, J.; Go, A. S. Body Mass Index and Risk for End-Stage Renal Disease. Ann. Intern. Med., 2006, 144, 21-28.
276. Muntner, P.; Winston, J.; Uribarri, J.; Mann, D.; Fox, C. S. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am. J. Med., 2008, 121, 341-348.
277. Van Gaal, L. F.; Mertens, I. L.; De Block, C. E. Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
278. Eknoyan, G. Obesity, diabetes, and chronic kidney disease. Curr. Diabetes Rep., 2007, 7, 449-453.
279. Knight, S. F.; Imig, J. D. Obesity, insulin resistance, and renal function. Microcirculation, 2007, 14, 349-362.
280. Kramer, H.; Luke, A. Obesity and kidney disease: A big dilemma. Curr. Opin. Nephrol. Hypertens., 2007, 16, 237-241.
281. Chien, K. L.; Hsu, H. C.; Lee, Y. T.; Chen, M. F. Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Atherosclerosis, 2008, 197, 860-867.
282. Despres, J. P.; Lemieux, I.; Bergeron, J.; Pibarot, P.; Mathieu, P.; Larose, E.; Rodes-Cabau, J.; Bertrand, O. F.; Poirier, P. Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1039-1049.
283. Lucove, J.; Vupputuri, S.; Heiss, G.; North, K.; Russell, M. Metabolic syndrome and the development of CKD in American Indians: The Strong Heart Study. Am. J. Kidney Dis., 2008, 51, 21-28
284. Morales, D. D.; Punzalan, F. E.; Paz-Pacheco, E.; Sy, R. G.; Duante, C. A. Metabolic syndrome in the Philippine general population: Prevalence and risk for atherosclerotic cardiovascular disease and diabetes mellitus. Diab. Vasc. Dis. Res., 2008, 5, 36-43
285. Bianchi, C.; Penno, G.; Daniele, G.; Russo, E.; Giovannitti, M. G.; Del, P. S.; Miccoli, R. The metabolic syndrome is related to albuminuria in Type 2 diabetes. Diabetes Med., 2008, 25, 1412-1418.
286. Ahmed, M. H. Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy? Expert Opin. Emerg. Drugs, 2006, 11, 563-565.
287. Nitsch, D.; Felber, D. D.; von Eckardstein, A.; Gaspoz, J. M.; Downs, S. H.; Leuenberger, P.; Tschopp, J. M.; Brandli, O.; Keller, R.; Gerbase, M. W.; Probst-Hensch, N. M.; Stutz, E. Z.; Ackermann-Liebrich, U. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: Results of the Swiss SAPALDIA study. Nephrol. Dial. Transplant., 2006, 21,
288. Retnakaran, R.; Cull, C. A.; Thorne, K. I.; Adler, A. I.; Holman, R. R. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes, 2006, 55, 1832-1839
289. Dixon, A.; Maric, C. 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am. J. Physiol. Renal. Physiol., 2007, 293, F1678-F1690.
290. Mankhey, R. W.; Bhatti, F.; Maric, C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am. J. Physiol. Renal. Physiol., 2005, 288, F399-F405.
291. Dixon, A.; Wells, C. C.; Singh, S.; Babayan, R.; Maric, C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am. J. Nephrol., 2007, 27, 120-128.
292. Hadjadj, S.; Gourdy, P.; Zaoui, P.; Guerci, B.; Roudaut, N.; Gautier, J. F.; Chabin, M.; Mauco, G.; Ragot, S. Effect of raloxifene - a selective oestrogen receptor modulator - on kidney function in post-menopausal women with Type 2 diabetes: Results from a randomized, placebo-controlled pilot trial. Diabet. Med., 2007, 24, 906-910.
293. Economides, P. A.; Caselli, A.; Tiani, E.; Khaodhiar, L.; Horton, E. S.; Veves, A. The Effects of Atorvastatin on Endothelial Function in Diabetic Patients and Subjects at Risk for Type 2 Diabetes. J. Clin. Endocrinol. Metab., 2004, 89, 740-747.
294. Buemi, M.; Floccari, F.; Nostro, L.; Campo, S.; Caccamo, C.; Sturiale, A.; Aloisi, C.; Giacobbe, M. S.; Frisina, N. Statins in the prevention of cardiovascular events in patients with renal failure. Cardiovasc. Hematol. Disord. Drug Targets, 2007, 7, 7-13.
295. Tonelli, M.; Keech, A.; Shepherd, J.; Sacks, F.; Tonkin, A.; Packard, C.; Pfeffer, M.; Simes, J.; Isles, C.; Furberg, C.; West, M.; Craven, T.; Curhan, G. Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease. J. Am. Soc. Nephrol., 2005, 16, 3748-3754.
296. Strippoli, G. F.; Navaneethan, S. D.; Johnson, D. W.; Perkovic, V.; Pellegrini, F.; Nicolucci, A.; Craig, J. C. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ, 2008, 336, 645-651.
297. Sukhija, R.; Bursac, Z.; Kakar, P.; Fink, L.; Fort, C.; Satwani, S.; Aronow, W. S.; Bansal, D.; Mehta, J. L. Effect of statins on the development of renal dysfunction. Am. J. Cardiol., 2008, 101, 975-979.
298. Fassett, R. G.; Ball, M. J.; Robertson, I. K.; Geraghty, D. P.; Coombes, J. S. The Lipid lowering and Onset of Renal Disease (LORD) Trial: A randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol., 2008, 9, 4.
299. Miyazaki, Y.; Cersosimo, E.; Triplitt, C.; DeFronzo, R. A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int., 2007, 72, 1367-1373.
300. Yang, J.; Zhang, D.; Li, J.; Zhang, X.; Fan, F.; Guan, Y. Role of PPARgamma in renoprotection in Type 2 diabetes: Molecular mechanisms and therapeutic potential. Clin. Sci. (Lond.), 2009, 116, 17-26.
301. Rizos, C. V.; Liberopoulos, E. N.; Mikhailidis, D. P.; Elisaf, M. S. Pleiotropic effects of thiazolidinediones. Expert Opin. Pharmacother., 2008, 9, 1087-1108.
302. Szeto, C. C.; Chow, K. M.; Poon, P. Y.; Kwan, B. C.; Li, P. K. Peroxisome Proliferator-Activated Receptor-Gamma Gene Polymorphism and Risk of Cardiovascular Disease in Patients with Diabetic Nephropathy. Am. J. Nephrol., 2008, 28, 715-722.
303. Psaty, B. M.; Furberg, C. D. Rosiglitazone and cardiovascular risk. N. Engl. J. Med., 2007, 356, 2522-2524.
304. Zheng, F.; Guan, Y. Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy? Kidney Int., 2007, 72, 1301-1303.
305. Cha, D. R.; Zhang, X.; Zhang, Y.; Wu, J.; Su, D.; Han, J. Y.; Fang, X.; Yu, B.; Breyer, M. D.; Guan, Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes, 2007, 56, 2036-2045.
306. Doggrell, S. A. Muraglitazar: Beneficial or detrimental in the treatment of Type 2 diabetes? Expert Opin. Pharmacother., 2006, 7, 1229-1233.
307. Varghese, Z.; Moorhead, J. F.; Ruan, X. Z. The PPARalpha ligand fenofibrate: Meeting multiple targets in diabetic nephropathy. Kidney Int., 2006, 69, 1490-1491.
308. Mohr, S. B.; Garland, C. F.; Gorham, E. D.; Garland, F. C. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia, 2008, 51, 1391-1398.
309. Zipitis, C. S.; Akobeng, A. K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis. Arch. Dis. Child, 2008, 93, 512-517.
310. Dobnig, H.; Pilz, S.; Scharnagl, H.; Renner, W.; Seelhorst, U.; Wellnitz, B.; Kinkeldei, J.; Boehm, B. O.; Weihrauch, G.; Maerz, W. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch. Intern. Med., 2008, 168, 1340-1349.
311. Li, Y. C. Vitamin D and diabetic nephropathy. Curr. Diabetes Rep., 2008, 8, 464-469.
312. Zhang, Z.; Sun, L.; Wang, Y.; Ning, G.; Minto, A. W.; Kong, J.; Quigg, R. J.; Li, Y. C. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int., 2008, 73, 163-171.
313. Zhang, Z.; Yuan, W.; Sun, L.; Szeto, F. L.; Wong, K. E.; Li, X.; Kong, J.; Li, Y. C. 1,25-Dihydroxyvitamin D3 targeting of NFkappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int., 2007, 72, 193-201.
314. Sugden, J. A.; Davies, J. I.; Witham, M. D.; Morris, A. D.; Struthers, A. D. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabetes Med., 2008, 25, 320-325.
315. Alborzi, P.; Patel, N. A.; Peterson, C.; Bills, J. E.; Bekele, D. M.; Bunaye, Z.; Light, R. P.; Agarwal, R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension, 2008, 52, 249-255.
316. New, J. P.; Aung, T.; Baker, P. G.; Yongsheng, G.; Pylypczuk, R.; Houghton, J.; Rudenski, A.; New, R. P.; Hegarty, J.; Gibson, J. M.; O'Donoghue, D. J.; Buchan, I. E. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: A population-based study. Diabetes Med., 2008, 25, 564-569.
317. Conway, B.; Fried, L.; Orchard, T. Hemoglobin and overt nephropathy complications in type 1 diabetes. Ann. Epidemiol., 2008, 18, 147-155.
318. Joss, N.; Patel, R.; Paterson, K.; Simpson, K.; Perry, C.; Stirling, C. Anaemia is common and predicts mortality in diabetic nephropathy. QJM, 2007, 100, 641-647.
319. Keane, W. F.; Zhang, Z.; Lyle, P. A.; Cooper, M. E.; de Zeeuw, D.; Grunfeld, J. P.; Lash, J. P.; McGill, J. B.; Mitch, W. E.; Remuzzi, G.; Shahinfar, S.; Snapinn, S. M.; Toto, R.; Brenner, B. M. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin. J. Am. Soc. Nephrol., 2006, 1, 761-767.
320. Abaterusso, C.; Pertica, N.; Lupo, A.; Ortalda, V.; Gambaro, G. Anaemia in diabetic renal failure: Is there a role for early erythropoietin treatment in preventing cardiovascular mortality? Diabetes Obes. Metab., 2008, 10, 843-9.
321. Khoshdel, A.; Carney, S.; Gillies, A.; Mourad, A.; Jones, B.; Nanra, R.; Trevillian, P. Potential roles of erythropoietin in the management of anaemia and other complications diabetes. Diabetes Obes. Metab., 2008, 10, 1-9.
322. Kingsmore, S. F.; Lindquist, I. E.; Mudge, J.; Gessler, D. D.; Beavis, W. D. Genome-wide association studies: Progress and potential for drug discovery and development. Nat. Rev. Drug Discov., 2008, 7, 221-230.
323. van Greevenbroek, M. M.; Zhang, J.; Kallen, C. J.; Schiffers, P. M.; Feskens, E. J.; de Bruin, T. W. Effects of interacting networks of cardiovascular risk genes on the risk of type 2 diabetes mellitus (the CODAM study). BMC Med. Genet., 2008, 9, 36.
324. Freedman, B. I.; Bowden, D. W.; Rich, S. S.; Xu, J.; Wagenknecht, L. E.; Ziegler, J.; Hicks, P. J.; Langefeld, C. D. Genome-wide linkage scans for renal function and albuminuria in Type 2 diabetes mellitus: The Diabetes Heart Study. Diabetes Med., 2008, 25, 268-276.
325. Iyengar, S. K.; Freedman, B. I.; Sedor, J. R. Mining the genome for susceptibility to diabetic nephropathy: The role of large-scale studies and consortia. Semin. Nephrol., 2007, 27, 208-222
326. Maeda, S.; Osawa, N.; Hayashi, T.; Tsukada, S.; Kobayashi, M.; Kikkawa, R. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int. Suppl., 2007, (106), S43-S48.
327. Vionnet, N.; Tregouet, D.; Kazeem, G.; Gut, I.; Groop, P. H.; Tarnow, L.; Parving, H. H.; Hadjadj, S.; Forsblom, C.; Farrall, M.; Gauguier, D.; Cox, R.; Matsuda, F.; Heath, S.; Thevard, A.; Rousseau, R.; Cambien, F.; Marre, M.; Lathrop, M. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: Strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes, 2006, 55, 3166-3174.
328. Tong, Z.; Yang, Z.; Patel, S.; Chen, H.; Gibbs, D.; Yang, X.; Hau, V. S.; Kaminoh, Y.; Harmon, J.; Pearson, E.; Buehler, J.; Chen, Y.; Yu, B.; Tinkham, N. H.; Zabriskie, N. A.; Zeng, J.; Luo, L.; Sun, J. K.; Prakash, M.; Hamam, R. N.; Tonna, S.; Constantine, R.; Ronquillo, C. C.; Sadda, S.; Avery, R. L.; Brand, J. M.; London, N.; Anduze, A. L.; King, G. L.; Bernstein, P. S.; Watkins, S.; Jorde, L. B.; Li, D. Y.; Aiello, L. P.; Pollak, M. R.; Zhang, K. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl. Acad. Sci. USA, 2008, 105, 6998-7003.
329. Schelling, J. R.; Abboud, H. E.; Nicholas, S. B.; Pahl, M. V.; Sedor, J. R.; Adler, S. G.; Arar, N. H.; Bowden, D. W.; Elston, R. C.; Freedman, B. I.; Goddard, K. A.; Guo, X.; Hanson, R. L.; Ipp, E.; Iyengar, S. K.; Jun, G.; Kao, W. H.; Kasinath, B. S.; Kimmel, P. L.; Klag, M. J.; Knowler, W. C.; Nelson, R. G.; Parekh, R. S.; Quade, S. R.; Rich, S. S.; Saad, M. F.; Scavini, M.; Smith, M. W.; Taylor, K.; Winkler, C. A.; Zager, P. G.; Shah, V. O. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: The family investigation of nephropathy and diabetes (FIND). Diabetes, 2008, 57, 235-243.
330. de Borst, M. H.; Benigni, A.; Remuzzi, G. Primer: Strategies for identifying genes involved in renal disease. Nat. Clin. Pract. Nephrol., 2008, 4, 265-276.
331. Ezquer, F. E.; Ezquer, M. E.; Parrau, D. B.; Carpio, D.; Yanez, A. J.; Conget, P. A. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol. Blood Marrow Transplant., 2008, 14, 631-640.
332. Hayashi, M. Development of new therapies, including regeneration of the kidney, for chronic kidney diseases. Clin. Exp. Nephrol., 2006, 10, 99-101.
333. Dean, P. G.; Kudva, Y. C.; Stegall, M. D. Long-term benefits of pancreas transplantation. Curr. Opin. Org. Transplant., 2008, 13, 85-90.
334. Spadella, C. T.; Machado, J. L.; Lerco, M. M.; Ortolan, E. V.; Marques, S. F. Pancreas transplantation prevents cellular oxidative stress in kidneys of alloxan-induced diabetic rats. Transplant. Proc., 2008, 40, 524-528.